Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE ZIDOVUDINE EFAVIRENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE ZIDOVUDINE EFAVIRENZ.
EMTRIVA vs LAMIVUDINE; ZIDOVUDINE; EFAVIRENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase by competing with natural substrates and causing chain termination. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing allosteric inhibition and preventing RNA-dependent DNA polymerization.
Emtricitabine 200 mg orally once daily.
One tablet (lamivudine 300 mg; zidovudine 300 mg; efavirenz 600 mg) orally once daily on an empty stomach, preferably at bedtime.
None Documented
None Documented
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Lamivudine: 5-7 hours in adults (prolonged in renal impairment). Zidovudine: 0.5-3 hours (terminal half-life), with intracellular active triphosphate half-life ~3 hours. Efavirenz: 40-55 hours (single dose), 10-20 hours at steady state (due to autoinduction), supporting once-daily dosing.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Lamivudine: renal (approximately 70% unchanged via glomerular filtration and active tubular secretion). Zidovudine: renal (approximately 14% unchanged, major metabolite G-ZDV 60-80% excreted in urine). Efavirenz: hepatic metabolism (CYP2B6, CYP3A4) with fecal (14-34%) and urinary (<1%) elimination.
Category C
Category A/B
Antiretroviral, NRTI
NRTI